Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesOphthalmology/OptometryAetna Epiretinal Radiation Therapy Coverage | Open…
    Ask Trek AI about this page
    CurrentAetnaPolicy 0756

    Epiretinal Radiation Therapy

    Customize your policy alerts

    Sign up for Aetna Policy 0756 alerts

    Get alerted when Policy 0756 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines Aetna's coverage stance on epiretinal radiation therapy, primarily for treatment of age-related macular degeneration (AMD) and related retinal conditions, and lists related policies and background evidence that inform the stance.

    Policy Summary
    PayerAetna
    PolicyEpiretinal Radiation Therapy
    Policy CodePolicy 0756
    Change TypeNo material change
    Effective DateMay 23, 2008
    Last ReviewOct 17, 2023
    Next Review DateAug 22, 2024
    Key ActionDo not submit claims for epiretinal radiation therapy for AMD or other conditions because it is considered experimental and investigational and is not covered.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    experimentalcoverage stance
    494phase III trial participants
    24 Gytypical dose
    3%radiation retinopathy
    10/17/2023last review

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Coverage Determinations

    Experimental / Investigational

    Coverage determination

    Experimental/Investigational Determination: Epiretinal radiation therapy is considered experimental and investigational for the treatment of age-related macular degeneration (AMD) or any other conditions because there is insufficient evidence and the effectiveness has not been established.

    From policy 'Experimental and Investigational' statement.

    Aetna considers epiretinal radiation therapy experimental and investigational for the treatment of age-related macular degeneration (AMD) or any other condition because there is insufficient evidence and the effectiveness of this approach has not been established.

    No explicit exclusions beyond the experimental/investigational determination are listed in the provided portion of the policy; the references section and cited trials are included but do not add additional exclusion language in the excerpt provided.

    The provided portion of the document does not state any procedures as not medically necessary; no not-medically-necessary statements are included in the excerpt.

    Related Codes and Dosage Information

    Related CPT CodesCPT
    67036Vitrectomy, mechanical, pars plana approach.
    Related ICD-10 CodesICD-10
    H35.30-H35.389Degeneration of macula and posterior pole
    Radiation dose used in studies
    Typical single-dose used in clinical studies24 Gy (single intraocular/epi-macular brachytherapy dose)
    Delivery modalityBeta radiation (strontium-90) delivered as a single treatment in reported trials
    Combination with anti-VEGFOften given in combination with intravitreal anti-VEGF injections (e.g., bevacizumab or ranibizumab) in studies

    Prior Authorization, Billing, and Clinical Actions

    Denial Risk

    Denial Risk for Epiretinal Radiation Therapy

    Aetna considers epiretinal radiation therapy experimental and investigational for the treatment of age-related macular degeneration (AMD) and other conditions; claims for this therapy are subject to denial on that basis.

    • Therapy considered experimental/investigational for AMD and other indications
    • Claims are at risk for denial because effectiveness has not been established
    Prior Authorization

    Prior Authorization / Step Therapy

    No prior authorization or step therapy requirements are specified in this policy. Providers should not assume prior authorization is required based on this document; check payer-specific enrollment or network instructions for any separate administrative requirements.

    • No prior authorization requirements stated in provided content

    Clinical Background

    Age-related macular degeneration (AMD) is a leading cause of irreversible vision loss and exists in dry and wet (neovascular) forms; wet AMD involves choroidal neovascular membranes that can cause rapid central vision loss. Because existing therapies (laser, photodynamic therapy, intravitreal anti-VEGF agents) have limitations, localized approaches such as epiretinal (epimacular) brachytherapy—including strontium-90 delivery systems used after vitrectomy—have been investigated as adjuncts or alternatives to standard care.

    Device and Procedure Definitions

    Epi-Rad90 Ophthalmic System / epiretinal strontium-90 brachytherapy
    Device nameEpi-Rad90 Ophthalmic System (NeoVista, Inc.)
    Radiation sourceStrontium-90 (beta radiation)
    Procedure contextDelivered after pars plana vitrectomy as a single intraocular application
    Intended indicationDeveloped to treat wet age-related macular degeneration (wet ARMD)
    Epiretinal (epimacular) brachytherapy
    DefinitionLocalized radiation therapy delivered to the macula (epiretinal/epimacular brachytherapy) to treat neovascular age-related macular degeneration and subfoveal choroidal neovascularization.
    Policy Summary
    PayerAetna
    PolicyEpiretinal Radiation Therapy
    Policy CodePolicy 0756
    Change TypeNo material change
    Effective DateMay 23, 2008
    Last ReviewOct 17, 2023
    Next Review DateAug 22, 2024
    Key ActionDo not submit claims for epiretinal radiation therapy for AMD or other conditions because it is considered experimental and investigational and is not covered.
    SourceLink
    On This Page
    Coverage DeterminationsRelated Codes and Dosage InformationPrior Authorization, Billing, and Clinical ActionsClinical BackgroundDevice and Procedure Definitions
  1. No step therapy requirements described in provided content
  2. Documentation Required

    Policy History and Documentation

    Documented policy history and review dates are provided in the policy header. Include the policy Effective Date and Next Review date when referencing this policy in administrative or clinical communications.

    • Effective Date: 2008-05-23
    • Next Review: 08/22/2024
    • Last Review: 10/17/2023
    Billing Rule

    Coding and Billing Note

    CPT, HCPCS and ICD-10 coding references are listed in the policy. Providers should use the coding section of the policy for billing and cross-check with current coding manuals; procedures related to vitrectomy (e.g., CPT 67036) and macular degeneration ICD-10 codes (H35.30 - H35.389) are referenced.

    • Referenced CPT: 67036 (vitrectomy, mechanical, pars plana approach)
    • Referenced ICD-10 range: H35.30 - H35.389 (degeneration of macula and posterior pole)
    Typical delivery
    Single 24 Gy epi-macular/epiretinal brachytherapy using an intraocular strontium-90/yttrium-90 source positioned over the lesion
    Adjunctive therapyPatients in studies were often retreated or supplemented with anti-VEGF injections per protocol